JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Nieuwssentiment

By Acuity

92%

6 / 347 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 mei 2026, 21:36 UTC

Acquisities, Fusies, Overnames

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mei 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mei 2026, 18:37 UTC

Belangrijke Marktbewegers

Senseonic Shares Slide on Underwritten Offering Price

1 mei 2026, 16:46 UTC

Belangrijke Marktbewegers

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 mei 2026, 19:57 UTC

Acquisities, Fusies, Overnames

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 mei 2026, 15:24 UTC

Winsten

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 mei 2026, 12:46 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 mei 2026, 08:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

1 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

1 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 mei 2026, 20:42 UTC

Winsten

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mei 2026, 19:33 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 mei 2026, 19:33 UTC

Marktinformatie

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mei 2026, 19:18 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mei 2026, 19:13 UTC

Marktinformatie

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mei 2026, 18:36 UTC

Winsten

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mei 2026, 18:35 UTC

Winsten

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mei 2026, 18:28 UTC

Winsten

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mei 2026, 18:27 UTC

Marktinformatie

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mei 2026, 18:14 UTC

Acquisities, Fusies, Overnames

Barclays Completes Acquisition of Best Egg

1 mei 2026, 18:04 UTC

Winsten

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mei 2026, 17:43 UTC

Marktinformatie

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mei 2026, 17:37 UTC

Marktinformatie

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mei 2026, 17:30 UTC

Marktinformatie

Winsten

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mei 2026, 17:28 UTC

Marktinformatie

Winsten

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mei 2026, 17:21 UTC

Marktinformatie

Winsten

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mei 2026, 17:19 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mei 2026, 16:38 UTC

Marktinformatie

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mei 2026, 16:23 UTC

Acquisities, Fusies, Overnames

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

6 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.